I am going to watch the trading on Monday and if it peaks from $8-$12 then I will sell somewhere in that range. But it all depends on how it trades.
But there are other things that also will come into play.
Did you read the labeling? I did and it seems that it is approved for all PBA:
INDICATIONS AND USAGE
NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a
variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and
frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or
incongruent to the underlying emotional state.
Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic
lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and
effective in other types of emotional lability that can commonly occur, for example, in
Alzheimer?’s disease and other dementias.
This is just one example. Does anyone have experience on label reading and what it means? I guess we will find out on the concall at 8:15am.
My point is that I believe the market is MUCH Bigger for AVNR than the $600M.
Also the analysts that follow it will IMO come out with higher targets since it is approved and also site a larger population. Also you will have new brokerage houses that have NOT issued opinions come out on AVNR as well, which should drive a lot more buyers. And will NEW potential shorts let it rise so they can short it at a much higher and possibly unrealistic price (higher than $12). Who knows?
So this could peak higher than my $8-$12 target.
It will be an interesting day on Monday.
